Eli Lilly and Company to invest in InduPro.

Eli Lilly and Company, a pharmaceutical company, agreed to invest in InduPro, a biotechnology company focused on creating novel protein-based medicines for cancer and autoimmune disease. Financial terms were not disclosed. Through the agreement, Lilly will gain access to InduPro’s proprietary AI/ML-enabled membrane interactomics platform. InduPro will lead early discovery efforts, applying its proximity-guided platform to identify co-target pairs and advance bispecific and multispecific antibody programs emerging from the collaboration.